Copaiba is named as an intervention in 2 current clinical trials in our Brazil register. 1 is recruiting patients now. The most common phase is Phase 1. The lead sponsor is Instituto Nacional de Cancer, Brazil. The most-studied condition is Head and Neck Neoplasms.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
Study of a Copaiba-Based Mouthwash Combined With Low-Level Laser Therapy in the Prevention of Oral Mucositis in Patients Undergoing Hematopoietic Stem Cell Transplantation
NCT07810530 · ClinicalTrials.gov ↗ · Oral Mucositis, Oral Mucositis (Ulcerative) Due to Antineoplastic Therapy, Oral Mucositis Due to Chemotherapy
|
Phase 2 | Recruiting | Instituto Nacional de Cancer, Brazil | Brazil |
|
Safety and Tolerability of the Use of Copaiba in Patients With Oral Cancer Submitted to Radiotherapy
NCT05308732 · ClinicalTrials.gov ↗ · Head and Neck Neoplasms, Mucositis Oral, Radiotherapy; Complications
|
Phase 1 | Active, closed | Instituto Nacional de Cancer, Brazil | Brazil |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Lead sponsor | Trials |
|---|---|
| Instituto Nacional de Cancer, Brazil | 2 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in Brazil | 2 | 1 |
A trial with sites in more than one country appears in each of those registers.
2 current trials in our Brazil register name Copaiba as a drug or biological intervention, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.
Yes. 1 of the 2 trials is recruiting: 1 with sites in Brazil. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
The lead sponsor is Instituto Nacional de Cancer, Brazil. The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Copaiba works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Copaiba works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Copaiba (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 26 Sep 2026.